5MP1 Stock Overview
A clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Biodexa Pharmaceuticals Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.65 |
| 52 Week High | US$156.25 |
| 52 Week Low | US$5.45 |
| Beta | 1.44 |
| 11 Month Change | 0% |
| 3 Month Change | -57.36% |
| 1 Year Change | -90.17% |
| 33 Year Change | -99.99% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5MP1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | -90.2% | -17.2% | 8.2% |
Return vs Industry: 5MP1 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 5MP1 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 5MP1 volatility | |
|---|---|
| 5MP1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine 5MP1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 21 | Stephen Stamp | www.biodexapharma.com |
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.
Biodexa Pharmaceuticals Plc Fundamentals Summary
| 5MP1 fundamental statistics | |
|---|---|
| Market cap | €2.55m |
| Earnings (TTM) | -€8.21m |
| Revenue (TTM) | €99.87k |
25.5x
P/S Ratio-0.3x
P/E RatioIs 5MP1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5MP1 income statement (TTM) | |
|---|---|
| Revenue | UK£83.00k |
| Cost of Revenue | -UK£62.00k |
| Gross Profit | UK£145.00k |
| Other Expenses | UK£6.96m |
| Earnings | -UK£6.82m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.74 |
| Gross Margin | 174.70% |
| Net Profit Margin | -8,215.66% |
| Debt/Equity Ratio | 0% |
How did 5MP1 perform over the long term?
See historical performance and comparison